Noninvasive eye scan detects Alzheimer's through plaque in retina

A noninvasive eye scan, developed by neuroscience investigators at Cedars-Sinai Medical Center in Los Angeles, detects Alzheimer’s disease years before symptoms arise by analyzing the amyloid-beta deposits in the retina. The study, published in JCI Insight, outlined how the scan improves current detection methods with high accuracy.

The number of people diagnosed with Alzheimer’s disease is set to triple by 2050, according to the Alzheimer’s Association. Current methods of detection involve expensive PET scans of the brain, which bars many patients from receiving the preventative care they need.

"The findings suggest that the retina may serve as a reliable source for Alzheimer's disease diagnosis," said the study's senior lead author, Maya Koronyo-Hamaoui, PhD, a principal investigator and associate professor in the departments of neurosurgery and biomedical sciences at Cedars-Sinai. "One of the major advantages of analyzing the retina is the repeatability, which allows us to monitor patients and potentially the progression of their disease."

Detection of Alzheimer’s with a noninvasive eye scan evaluates plaque build-up in the retina, which reflects the plaque in the brain. The noninvasive exam allows for a broader range of patients to access preventative care years before symptoms arise, improving patient outcomes.

"Our hope is that eventually the investigational eye scan will be used as a screening device to detect the disease early enough to intervene and change the course of the disorder with medications and lifestyle changes," said Keith L. Black, MD, chair of Cedars-Sinai's Department of Neurosurgery and director of the Maxine Dunitz Neurosurgical Institute and co-lead of the study.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup